Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | CASP6 | P55212 | 2/20 | 0.35 |
| ▸ | DNA2 | P51530 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.35 |
| ▸ | FBP1 | P09467 | 7/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2388710 | 0.74 | TSHR (0.50) | TPMTCYP1A2CYP2C9TSHRCASP6 | |
| SCHEMBL28052757 | 0.67 | TSHR (0.58) | CYP1A2CYP2C9TSHRCASP6DNA2 | |
| SCHEMBL4936434 | 0.66 | TSHR (0.44) | CYP1A2CYP2C9TSHRCASP6DNA2 | |
| SCHEMBL20568749 | 0.66 | MAPT (0.40) | CYP1A2CYP2C9TSHRLMNATDP1 | |
| SCHEMBL28036125 | 0.66 | TDP1 (0.44) | CYP1A2TSHRCASP6TDP1 | |
| SCHEMBL8963317 | 0.66 | KDM4E (0.40) | CYP1A2TSHRTDP1L3MBTL1GPR35 | |
| Ammonia Solution, Strong SCHEMBL16243724 | 0.65 | TSHR (0.43) | CYP1A2CYP2C9TSHRCASP6DNA2 | |
| SCHEMBL14267778 | 0.63 | GPR35 (0.40) | TSHRCASP6DNA2CTDSP1TDP1 | |
| SCHEMBL4703943 | 0.63 | KMT2A (0.43) | CYP1A2CYP2C9TSHRLMNATDP1 | |
| SCHEMBL7811994 | 0.63 | POLB (0.42) | CYP2C9TSHRLMNATDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210137884-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210137884-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | MGAM, GAA, ALPI | TPMT 81/4885CYP1A2 131/4885CYP2C9 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.